Cell line-directed breast cancer research based on glucose metabolism status

Metabolic reprogramming is a potential hallmark of tumor cells to support continuous proliferation. Metabolic heterogeneity in breast cancer patients has been highlighted as the driving cause of tumor progression and resistance to anticancer drugs. Studying and identifying distinct metabolic alterations in breast cancer subtypes could offer new perspectives for faster diagnosis and treatment. Given cancer cell dependency on glycolysis, the primary energy source, this enzymatic pathway will play a critical role in targeting therapies. Knowledge about the specific metabolic dependencies of tumors for growth and proliferation can be promising for novel targeted and cell-based therapies. Here, the metabolic status with emphasis on glycolysis of breast cancer cell lines according to their classification was reviewed.

Automated summary

Metabolic reprogramming is a potential characteristic of tumor cells for continuous proliferation, with metabolic heterogeneity in breast cancer patients driving tumor progression and resistance to anticancer drugs. Identifying distinct metabolic alterations in breast cancer subtypes could provide new perspectives for faster diagnosis and treatment.